Evotec SE Form 6-K Summary (Nov 2025)

Evotec SE reported a material business event on November 4, 2025, announcing a final agreement with Sandoz.

• Transaction Highlight: The agreement involves a portfolio of up to 10 biosimilar molecules.
• Financial Impact:
  • Potential payments exceeding US$ 650 million.
  • Inclusion of ongoing royalties.

This represents a significant strategic transaction for the Company. The filing confirms Christian Wojczewski, CEO, signed the report.

This transaction is described as a “landmark industry transaction.”

E